Theriva Biologics Faces Financial Risks Amid Shifting Trade Policies and Tariffs

Theriva Biologics, Inc. (TOVX) has disclosed a new risk, in the Capital Markets category.

Theriva Biologics, Inc. faces significant business risks due to potential changes in trade policy, including tariffs and customs regulations. These changes could arise from shifts in U.S. or international political, regulatory, and economic conditions, affecting the company’s operations and financial health. The imposition of tariffs, particularly in key markets like China, where they have engaged vendors, could lead to retaliatory measures, impacting their business and reputation. Additionally, protectionist trends could further complicate the trade environment, posing a material threat to their financial condition and operational results.

The average TOVX stock price target is $7.00, implying 1,554.85% upside potential.

To learn more about Theriva Biologics, Inc.’s risk factors, click here.